Expanded Access Program for Lorcaserin (Belviq)

Brief description of study

The purpose of this extended access program is to provide continued access to lorcaserin for Dravet syndrome and other epilepsy patients who were being treated with lorcaserin before the US Food and Drug Administration (FDA) withdrew approval of the drug and who may have benefited from the treatment. Lorcaserin is not approved by the FDA or any other regulatory agency for any conditions or diseases. As lorcaserin has not been studied in Dravet syndrome or other epilepsies, there is no guarantee that lorcaserin will improve your seizure control.


Clinical Study Identifier: s20-00271
Principal Investigator: Orrin Devinsky.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.